Mensil Max

Sildenafil citrate, the active ingredient in Mensil Max, is a phosphodiesterase type 5 (PDE5) inhibitor presented as an oral tablet for oral use. It treats erectile dysfunction in adult males by facilitating penile erection when sexual stimulation occurs. GNH USA supplies Mensil Max as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mensil Max, a PDE5 inhibitor, is used to manage conditions related to vascular smooth‑muscle tone. - Erectile dysfunction: improves the ability to achieve and maintain an erection during sexual activity. - Pulmonary arterial hypertension: reduces pulmonary arterial pressure and enhances exercise capacity in affected patients. - Severe pulmonary hypertension in newborns: approved in certain regions for reducing pulmonary vascular resistance in neonatal patients.

Sildenafil is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain often occurring shortly after dosing. - Flushing: warmth and redness of the face or upper chest. - Dyspepsia: indigestion or upset stomach. - Nasal congestion: stuffy or runny nose. - Visual disturbances: blurred vision or color tinge changes. - Back pain: muscle ache, typically 12‑24 hours post‑dose.

Serious or Rare Side Effects: - Priapism: prolonged erection lasting more than four hours, requiring urgent medical attention. - Sudden hearing loss: unexplained decrease or loss of hearing. - Cardiovascular events: rare cases of myocardial infarction or stroke, especially in patients with pre‑existing heart disease.

Before prescribing Mensil Max, clinicians should evaluate patient risk factors and contraindications. - Cardiovascular assessment: ensure patient can tolerate sexual activity. - Nitrate use: avoid concurrent administration with nitrates or nitric‑oxide donors. - Hepatic impairment: use with caution in severe liver disease. - Alcohol consumption: limit excessive intake as it may increase side‑effects. - Blood pressure monitoring: watch for symptomatic hypotension. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Sildenafil may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Nitrates (e.g., nitroglycerin): risk of severe hypotension. - Guanylate cyclase stimulators (e.g., riociguat): additive vasodilatory effect. - Other PDE5 inhibitors: increased risk of adverse events.

Moderate Interactions (Monitor Closely): - Alpha‑blockers: may cause additive blood pressure lowering. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase sildenafil plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce efficacy of sildenafil. - Antihypertensives: monitor for enhanced hypotensive response.